Abstract:Case: Introduction:Fecal calprotectin is a known inflammatory marker used to evaluate patients with Inflammatory Bowel Disease (IBD). In fact, ACG Clinical Guideline for management of Crohn's disease recommend fecal calprotectin (FC) as a helpful test to distinguish IBD versus functional disorder such as Irritable Bowel Syndrome. Studies have also shown association of fecal calprotectin with colon cancer. Recent study proposed fecal calprotectin could be a reliable marker for ruling out organic disease with high negative predictive value. Case description: We present a patient case of a Caucasian, thirty-five years of age male with PMHx of GERD on Prilosec who presented due to acute abdominal pain, nausea, emesis and watery, nonbloody diarrhea of four days duration. Initially, patient had unknown family history of colon cancer which later was revealed that patient's father had a colon cancer diagnosis in his fifties. On admission, patient had stable vitals with routine labs showing leukocytosis, iron deficiency anemia, normal CRP, and elevated fecal calprotectin of 986mcg/gm. Abdominal imaging with CT abdomen with contrast showed diffuse dilation of ileum and thickening of the distal ileum up to the level of the ileocecal junction, suggestive of enteritis from infectious or inflammatory etiology such as Crohn's. Patient was managed conservatively, stool studies were negative otherwise and discharged with outpatient endoscopy due to high suspicion for Inflammatory Bowel Disease. Within one week, patient had a subsequent readmission for now partial small bowel obstruction at the level of ileum. Due to high suspicion of Crohn's, patient was empirically started on IV steroids. Decision for inpatient colonoscopy was made with colonoscopy showing completely obstructing, circumferential, large mass found in the cecum extending into ascending colon. Final pathology revealed invasive mucinous adenocarcinoma, moderately differentiated. Patient subsequently underwent right hemicolectomy with lymph node resection and adjuvant chemotherapy treatment for stage 3 colon. Discussion: We present here a case where a common cancer was found in an otherwise healthy, young male with acute abdominal pain and altered bowel habits. While initial symptoms, imaging and laboratory findings pointed towards a biased high suspicion for Inflammatory Bowel Disease, patient's ultimate diagnosis was stage 3 adenocarcinoma of colon requiring surgical resection and chemotherapy. Fecal calprotectin is a known marker for colon inflammation and associated with both IBD and colon cancer. It is important to keep in mind that while fecal calprotectin may have elevated negative predictive value and be used to rule out organic disease, elevation of fecal calprotectin is not always specific for IBD. We want to emphasize the importance of considering colon cancer on the differential despite a patient's age and diagnostic bias. Lastly, we also want to highlight the importance of tissue diagnosis prior to long term therapy use.

Fecal calprotectin in differential diagnosis of irritable bowel syndrome]

Clinical value of fecal calprotectin

Comparison of Fecal Calprotectin with Different Endoscopic Scores in the Assessment of Ulcerative Colitis (UC) Activity and Its Utility in Differentiating IBS from IBD

Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome

Evaluation of a Fluorescent Immunochromatography Test for Fecal Calprotectin

Clinical Spectrum in a Cohort of Patients With High Fecal Calprotectin Levels

P019 Not All Fecal Calprotectin is Specific for Inflammatory Bowel Disease

Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease

Biological functions and clinical significance of calprotectin. Review

Research about the Diagnostic and Predictive Value of Fecal Calprotectin in Ulcerative Colitis

P473 Comparison of clinical performance of fecal calprotectin of laboratory methods with lateral flow based POC and home tests

Application of Fecal Calprotectin and Myeloperoxidase in Evaluation of Disease Activity of Ulcerative Colitis

Experimental infectious challenge in pigs leads to elevated fecal calprotectin levels following colitis, but not enteritis

P282 High Correlation Between Fecal Immunochemical Test and Fecal Calprotectin for the Evaluation of Activity in Inflammatory Bowel Disease

Fecal calprotectin diagnostic level gradient along the small bowel in patients with Crohn's disease

P275 Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of Crohn’s disease

Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease

Clinical Comparison of OC-Sensor Pledia and Phadia 250 for Fecal Calprotectin Testing

Evaluating the efficacy of fecal immunochemical test, fecal calprotectin, and serum C-reactive protein in diagnosing patients with chronic lower gastrointestinal symptoms

P371 Calprotectin Testing: A Methods Comparison Study

Fecal Calprotectin in Patients with Crohn's Disease: A Study Based on the History of Bowel Resection and Location of Disease